Medtronic (NYSE:MDT) Price Target Lowered to $86.00 at Truist Financial

Medtronic (NYSE:MDT) had its price objective cut by Truist Financial from $95.00 to $86.00 in a research note issued to investors on Thursday,MarketScreener reports. The firm currently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price objective would indicate a potential upside of 4.53% from the stock’s current price.

A number of other analysts have also weighed in on MDT. Citigroup dropped their target price on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. UBS Group restated a “neutral” rating and set a $85.00 price target on shares of Medtronic in a report on Thursday. Leerink Partners lowered their price target on Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research report on Thursday. BTIG Research set a $90.00 price objective on Medtronic in a report on Wednesday. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $88.00 price objective on shares of Medtronic in a research report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.45.

Medtronic Trading Up 5.5%

MDT stock traded up $4.32 during midday trading on Thursday, hitting $82.27. The company had a trading volume of 2,865,182 shares, compared to its average volume of 9,074,854. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The stock’s 50 day moving average price is $81.67 and its 200 day moving average price is $92.21. The stock has a market cap of $105.63 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts expect that Medtronic will post 5.54 earnings per share for the current fiscal year.

Institutional Trading of Medtronic

Several large investors have recently bought and sold shares of MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic in the 4th quarter valued at approximately $27,000. Lodestone Wealth Management LLC purchased a new stake in Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC raised its holdings in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Board of the Pension Protection Fund bought a new position in Medtronic in the fourth quarter worth $29,000. Finally, GoalVest Advisory LLC purchased a new position in Medtronic during the fourth quarter valued at $29,000. 82.06% of the stock is owned by institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).